- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:38 | Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing | 145 | ACCESS Newswire | The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV... ► Artikel lesen | |
| Fr | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | Medicus Pharma Ltd. Provides Update on United Arab Emirates SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin | 237 | ACCESS Newswire | CLEVELAND CLINIC ABU DHABI (CCAD) HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 8, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus"... ► Artikel lesen | |
| 02.09. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | Medicus Pharma Ltd. Completes Acquisition of Antev Limited | 391 | Newsfile | Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma... ► Artikel lesen | |
| 22.08. | Medicus Pharma Ltd. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.08. | Medicus Pharma Ltd. reports Q2 results | 1 | Seeking Alpha | ||
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 21.08. | Medicus Pharma erzielt Fortschritte bei Hautkrebsmittel vor FDA-Gespräch | 2 | Investing.com Deutsch | ||
| 21.08. | Medicus Pharma advances skin cancer treatment as FDA meeting approaches | 1 | Investing.com | ||
| 21.08. | Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights | 216 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - August 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development... ► Artikel lesen | |
| 11.08. | Medicus Pharma Ltd. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.08. | Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines | 283 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - August 4, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Helix Nanotechnologies Inc. ("HelixNano"), a Boston-based biotech company focused... ► Artikel lesen | |
| 04.08. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.07. | Medicus Pharma Ltd. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.07. | Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders | 345 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - July 23, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the voting results of the Company's annual and... ► Artikel lesen | |
| 21.07. | Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025 | 297 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - July 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the scheduling of the Fireside chat of Dr. Raza... ► Artikel lesen | |
| 14.07. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA) | 300 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - July 8, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive package to the United... ► Artikel lesen | |
| 04.07. | Medicus Pharma: Pflaster gegen Hautkrebs - ein Investment wert? | 628 | sharedeals.de | Eine hierzulande wohl ziemlich unbekannte Aktie ist die von Medicus Pharma. Das Unternehmen aus Kanada ist seit Ende letzten Jahres auch an der US-Nasdaq gelistet und hat Großes vor. Wenn der Plan aufgeht... ► Artikel lesen | |
| 30.06. | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings |
1 2 3 4 Weiter >>
73 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 20,440 | +0,54 % | Investor Woche: EZB hält Zinsen stabil, Fed vor Dilemma, Klarna mit starkem IPO, Novo Nordisk streicht stellen, Pfizer, Prismo Metals, Sotheby's, Larry Ellison, Elon Musk | EZB belässt Zinsen stabil. Die Fed dürfte kommende Woche trotz hartnäckiger Inflation wegen dem schwachen Arbeitsmarkt die Zinsen senken. Klarna mit starkem IPO, Sotheby's leidet am Kunstmarkt. Novo... ► Artikel lesen | |
| GILEAD SCIENCES | 95,86 | +0,94 % | Dividendenbekanntmachungen (15.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A&W FOOD SERVICES OF CANADA INC CA0002251027 0,48 CAD 0,2954 EUR ALLEGION PLC IE00BFRT3W74 0,51 USD 0,4345 EUR ALTRIA GROUP INC US02209S1033 1... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 327,70 | +0,08 % | Vertex Pharmaceuticals: Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy | - CASGEVY is the first, and only, gene editing therapy approved for the treatment of transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD) in Europe - - Italy has the largest... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 11,495 | -0,48 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of... ► Artikel lesen | |
| ROCKET LAB | 41,400 | +1,47 % | Wochenrückblick 37/2025: Meine stärksten Kurstreiber im Depot waren Rocket Lab, Almonty, Rheinmetall, AeroVironment, Broadcom und trieben es auf Jahreshoch. Fast... | Die Top-Werte meines Investmentdepots veröffentliche ich jeweils zum Quartalsende in meinen Investor-Updates und meine Beobachtungsliste aktualisiere ich wöchentlich.Ergänzend gebe ich heute eine kurze... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 6,450 | +2,38 % | H.C. Wainwright hebt Kursziel für Astria Therapeutics auf 20 US-Dollar an | ||
| OPKO HEALTH | 1,171 | -0,70 % | OPKO HEALTH, INC. - 8-K, Current Report | ||
| LIGAND PHARMACEUTICALS | 140,00 | 0,00 % | LIGAND PHARMACEUTICALS INC - 8-K, Current Report | ||
| JAZZ PHARMACEUTICALS | 109,05 | -0,50 % | Piper Sandler reiterates Overweight rating on Jazz Pharmaceuticals stock | ||
| UNITED THERAPEUTICS | 339,40 | -0,56 % | Aktien New York: Steigende US-Zinsen und schwache Techwerte belasten | NEW YORK (dpa-AFX) - Steigende Zinsen an den Kapitalmärkten und teils stark fallende Technologieaktien haben am Dienstag die großen US-Aktienindizes belastet. Der Leitindex Dow Jones Industrial fiel... ► Artikel lesen | |
| ROYALTY PHARMA | 29,970 | -0,63 % | Royalty Pharma Expects At Least Mid-teens Average Annual Total Shareholder Return Over 2025-2030. | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) Thursday said it will host an Investor Day today, where senior executives will provide updates on the company's strategies aimed at driving shareholder... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 16,805 | -0,77 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals | CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 43,980 | +1,59 % | BridgeBio: H.C. Wainwright bestätigt "Buy"-Rating wegen Potenzial von Encaleret | ||
| TG THERAPEUTICS | 27,350 | +0,92 % | TG Therapeutics, Inc.: TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment | NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy)... ► Artikel lesen | |
| AVADEL PHARMACEUTICALS | 13,200 | 0,00 % | Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding | A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation)... ► Artikel lesen |
MEDICUS PHARMA LTD gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,110 (+4,51 %) liegt der Kurs bei 2,550 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.